港股创新药概念股走低，相关ETF跌约3%

Group 1 - The core viewpoint indicates that Hong Kong's innovative pharmaceutical stocks have declined, with notable drops in companies such as Kelun-Botai Biopharmaceuticals falling over 6%, and others like 3SBio and Zai Lab dropping over 5% [1] - Multiple Hong Kong innovative pharmaceutical-related ETFs have also experienced a decline of approximately 3% [2] - Analysts suggest that after a decade of transformation, China's innovative pharmaceutical industry is entering a phase of realization, with a steady increase in the number of domestic innovative drugs approved for market and significant overseas transactions [3]